Autologous Application of UC-MSCs to Treat Type 1 Diabetes (T1D)
Type 1 Diabetes — T1DM is a chronic autoimmune disease in which the immune system destroys insulin-producing beta cells located in the pancreas. When the function of beta cells declines, this means that less insulin is produced in response to elevated glucose levels and blood glucose rises. Type 1 Diabetes is traditionally treated with insulin therapy, blood glucose monitoring, nutritional planning, physical activity and long term medical care. These are still the basic components and should not be replaced. According to current scientific reviews, Type 1 Diabetes (T1D) is described as an autoimmune disease characterized by the destruction of beta-cells and autoantibodies leading to endogenous insulin production decline.
In recent years, UC-MSCs has drawn interest in Type 1 Diabetes (T1D) studies with stem cell therapy. It has been recognized that umbilical cord-derived mesenchymal stem/stromal cells (UC-MSCs) can perform biological signaling to balance the immune status, inhibit the exaggeration of inflammation and protect remaining beta-cell environment. This way is not really to start by replacing insulin right away. Rather, the focus is to aid the endogenous environment that mediates immune modulation in addition to pancreatic function.
What Are UC-MSCs?
UC-MSCs are mesenchymal stem/stromal cells obtained from the human umbilical cord tissue isoleted after healthy childbirth. They are extensively investigated due to their capacity to secrete biologically active substances such as growth factors, cytokines, extracellular vesicles, and other factors involved in paracrine signaling.
UC-MSCs are especially interesting for Type 1 Diabetes, as the condition is immune-driven. The most promising value of UC-MSCs is their ability to interact with immune cells and inflammatory signaling pathways, not just replace lost pancreatic cellular mass.
Is there a way to fix type 1 diabetes with stem cells?
Supporting Immune Balance
Type 1 Diabetes -> pancreatic beta cell destruction due to misguided immune attack. Interacting with immune cells such as T and B lymphocytes, macrophages, and regulatory T cells suggests an important role for UC-MSCs in regulating local immune activity. This might facilitate a more physiologic immune response and lessen the autoimmune burden on residual beta cells.
This immune-modulating function is one of the primary factors for which stem cell therapy for Type 1 Diabetes is being investigated as a supportive regenerative approach.
Helping Preserve Beta-Cell Function
Preserving beta-cell function is one of the most important goals of Type 1 Diabetes care as far as possible. Insulin is secreted from beta cells and even partial preservation of this population may allow better glucoregulatory performance.
Interest in preserving endogenous insulin secretion has arisen in clinical studies investigating Wharton’s jelly-derived mesenchymal stem cells (MSCs) for their potential in early Type 1 Diabetes. A clinical translation review describes one phase I/II randomized study that observed smaller decrease of C-peptide in UC-MSC intervention group vs. placebo over 12 months, indicating potential beta-cell function support for some patients.
The action of C-Peptide and Endogenous Insulin
C-peptide is used in general as a marker of the production of insulin by one´s own body. In Type 1 Diabetes (like Sp1c), the other is C-peptide which decrease as beta-cell function fail.
A few clinical studies and reviews indicate that, in some selected patients at eligible disease stages, MSC-based approaches can support C-peptide levels. The authors of a systematic review and meta-analysis of randomized controlled trials published in 2025 reported that MSC therapy was associated with improvements in fasting C-peptide following the therapy at 12 months — although individual trial data were mixed.
Figure 1: C-Peptide as a Marker of Endogenous Insulin Activity in Type 1 Diabetes
Helping Reduce Inflammatory Stress
Immune Activation and Inflammation Chronic immune activation and inflammation are central aspects of Type 1 Diabetes (T1D) pathology. Despite this, UC-MSCs can also secrete anti-inflammatory signals that reflects the overall health of mRNA and helps to ease hyperactivated immune response. This might enable the establishment of a healthier pancreatic microenvironment and alleviate biological stress in surviving beta cells.
We do not want to turn off the immune system totally, we want better immune modulation from your own immune system.
Supporting Better Metabolic Stability
UC-MSCs have the potential to provide metabolic balance in selected patients when combined as an adjuvant with standard diabetes treatment. Possible supportive goals may include:
Better glucose stability
Reduced inflammatory burden
Support for remaining beta-cell function
More Insulin Secreting Cell Potential Type Eviroments
possible decreased insulin need in selected individuals
Support for long-term wellness and quality-of-life
The advantages depend heavily on patient selection, disease duration, remaining beta-cell reserve age, metabolic state, autoimmune activity and lifestyle and medical management.
The Role of Timing in Type 1 Diabetes
Our further review suggests that stem cell therapy with UC-MSCs may be more feasible and effective when some degree of beta-cell function remains. With new-onset Type 1 Diabetes, measurable C-peptide may still be found, suggesting the pancreas is able to produce a minimal quantity of actual insulin. This residual function is one of the main questions to be solved by research.
Beta-cell reserve may be even less in long-term Type 1 Diabetes, so the target we might expect could become immune balance rather than preservation of function or inflammation support and general metabolic health over time.
Who May Consider UC-MSC Support?
Select patients may be thx of a UC-MSC stem cell therapy program for Type 1 Diabetes but are carefully evaluated on an individual’s medical history and clinical tests. Doctors may review:
Duration of type 1 diabetes at diagnosis:
C-peptide level
HbA1c and glucose pattern
Daily insulin requirement
Autoimmune markers
Kidney and liver function
Infection screening
Current medication and insulin plan
Overall health condition
Given that Type 1 Diabetes involves optimal glucose management before, during and after any supportive treatment, this is crucial.
Important Medical Note
Should not be called a cure for Type 1 Diabetes with UC-MSCs stem cell therapy. It is not a substitute for insulin, glucose monitoring, endocrinology management, nutrition planning or emergency treatment of hypoglycemia or ketoacidosis.
Recent evidence indicates that UC-MSCs may exhibit supportive roles, particularly regarding immune modulation and beta-cell preservation research; however, protocols, dose, timing, patient selection, and long-term outcomes require further exploration. Reviews highlight that MSC-based strategies are still under development and need additional clinical validation.
Conclusion
The use of stem cell therapy with umbilical cord mesenchymal stem cells (UC-MSCs) for Type 1 Diabetes is an immature excellently developed supportive therapeutic area in embryonic-like regenerative medicine. It may help balance the immune response, control inflammation, support beta-cell function as well as prevent C-peptide loss and achieve more favorable internal conditions to promote metabolic stability.
UC-MSCs could provide an extra adjunctive support option with standard of care Type 1 Diabetes for selected patients. This method, however, should always be balanced with clinical assessment, realistic expectations and ongoing endocrinology follow-up.